Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px
Document › Details

Applied Proteomics Inc.. (2/7/12). "Press Release: Applied Proteomics Appoints Peter Klemm as CEO Following Series B Financing of $22.5 Million". San Diego, CA.

Region Region San Diego, CA
  Country United States (USA)
Organisation Organisation Applied Proteomics Inc. (API)
Products Product proteomic marker (diagnostics)
  Product 2 molecular diagnostics
  Index term 2 Applied Proteomics–SEVERAL: investment, 201202 financing round Series B $22.5m from Domain Assoc + Vulcan Capital + returning angel investors
Person Person Klemm, Peter (Applied Proteomics 201202– CEO before Predictive BioSciences CEO + BD-GeneOhm + GeneOhme Sciences)
     


Applied Proteomics Inc. (API), powering the proteome to transform diagnostics, announced today the appointment of veteran diagnostic developer, Peter Klemm, Ph.D., as chief executive officer. API also announced the move of the corporate headquarters to San Diego. Prior to the move, API secured a $22.5 million Series B financing from Domain Associates, Vulcan Capital and returning angel investors. In conjunction with the financing, James C. Blair, Ph.D. founding partner at Domain, joined the Company's board of directors. The financing will support the creation of new diagnostics based on API's proprietary proteomic platform solution to significantly improve medical care and therapeutic development.

"Improving healthcare starts with improving diagnostics. Better diagnostics provide better information about the patient's health state and treatment response and that in turn leads to the delivery of more personalized medical care and the development of better therapies," said David Agus, M.D., co-founder of API and director of the USC Center for Applied Molecular Medicine and the USC Westside Cancer Center. "API has significantly advanced the technology to look at the whole proteome instead of a single protein biomarker and have a complete picture of a patient's status to make the best healthcare decisions."

"For the first time, we can look at all the proteins in the body with remarkable specificity and sensitivity and use proteomic technology to create superior diagnostics that can 'listen to the conversation of the body,'" stated Daniel Hillis, co-founder of API and chairman and CTO of Applied Minds. "Dr. Klemm brings years of experience and success in diagnostic development, and his addition to the leadership team comes at a key time to advance API's mission to create transformative proteome-based diagnostics that will significantly improve medical diagnosis and treatments."

Through technological innovation and novel approaches, API has solved the proteomics problem by rapidly collecting, processing, and analyzing data and identifying actionable medical information. With unique mass spectrometry-based systems control and computational expertise, API's proteomics platform solution can accurately, reproducibly, and efficiently take "snapshots" of a patient's proteome and provide a physiological picture of the proteins actually expressed in the body. Because proteins perform most cellular functions and are the targets of most drugs and therapies, they are the most powerful source of information to know the health status of the patient. API is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care.

"In addition to API's industry-leading proteomics platform, we have a great foundation from our investors, including a deep commitment from our returning angels, a depth of experience from Domain and Dr. Jim Blair, and an innovation community with Vulcan Ventures," said Dr. Klemm, CEO of API. "We are motivated to quickly advance the development of new proteome-based diagnostics that will significantly improve the way medical decisions are made and how patients are diagnosed and treated."

Dr. Klemm has extensive experience in building markets for novel high-value diagnostic tests. Dr. Klemm currently serves as chairman of Pathwork Diagnostics and previously served as CEO and president of Predictive Biosciences and CEO of GeneOhm Sciences, which he joined in 2002 and was acquired by Becton Dickinson. Prior to GeneOhm Sciences, he was CEO of JOMED, senior vice president of research and development of Gruenenthal GmbH, and senior scientist at Aventis. Dr. Klemm joins John E. Blume, Ph.D., who has been CSO at Applied Proteomics since 2008.

About Applied Proteomics Inc.

Applied Proteomics Inc. (API) is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems. API's platform combines improved instrumentation, faster computing and extensive genome annotations with regimented standard operating procedures, extensive quality controls, and documented processes spanning hundreds of steps from sample collection to processing through informatics. API is currently advancing several internal diagnostic development programs. API is headquartered in San Diego, CA. For more information, please visit http://www.appliedproteomics.com.

   
Record changed: 2016-03-19

Advertisement

Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 600x60px

More documents for Applied Proteomics Inc. (API)


To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px BCNP Consultants European Chemistry Partnering 2017 Ffm Germany 120x180px Picture EBD Group BIO-Europe Spring 2017 BES Barcelona Spain March 120x180px Picture AB Sciex Berliner LCMSMS Symposium 2017 Right 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px